Trial Profile
A Phase Ib/II Trial of M7824 in Solid Tumors With Microsatellite Instability With Consensus Molecular Subtype 4 Metastatic Colorectal Cancer in Combination With Radiation, or in Colorectal Cancer Patients With Detectable Circulating Tumor DNA Following Definitive Therapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Bintrafusp alfa (Primary)
- Indications Adenocarcinoma; Carcinoma; Colon cancer; Colorectal cancer; Duodenal cancer; Pancreatic cancer; Rectal cancer; Solid tumours
- Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 28 Mar 2023 Planned End Date changed from 1 Nov 2022 to 1 Aug 2023.
- 28 Mar 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Aug 2023.
- 12 Jan 2022 Planned End Date changed from 1 Nov 2021 to 1 Nov 2022.